Sign In
Buy FULC
$3.22
+0.0800 (+2.55%)
At Close: Jun 03, 2026
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
07:01am, Tuesday, 10'th Aug 2021
– Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology –
Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know
04:47pm, Tuesday, 03'rd Aug 2021
Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
04:19pm, Wednesday, 12'th May 2021
The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is on trac
CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q1 2021 Results - Earnings Call Transcript
03:19pm, Saturday, 08'th May 2021
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q1 2021 Results - Earnings Call Transcript
Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
07:00am, Friday, 07'th May 2021
CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
07:01am, Thursday, 06'th May 2021
– On track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) at virtual FSHD International Research Congress in June 2021 –
Company initiates dosing in Phase 1 healthy volunteer multiple ascending dose (MAD) cohort Company initiates dosing in Phase 1 healthy volunteer multiple ascending dose (MAD) cohort
Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D.
09:29am, Wednesday, 24'th Mar 2021
CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
FULC Stock Price Increases Over 40% Pre-Market: Why It Happened
06:45am, Tuesday, 23'rd Mar 2021
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) increased by over 40% pre-market. This is why it happened.
– Demonstrated Whole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with FSHD clinical endpoints –
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q4 2020 Results - Earnings Call Transcript
01:43pm, Thursday, 04'th Mar 2021
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q4 2020 Results - Earnings Call Transcript
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
09:08am, Thursday, 04'th Mar 2021
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 12.33% and 153.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
07:01am, Thursday, 04'th Mar 2021
– Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021 –
